Uridine triacetate
(Synonyms: 2',3',5'-三乙酰尿苷,Tri-O-acetyl uridine) 目录号 : GC38302
A prodrug of uridine
Cas No.:4105-38-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
2’,3’,5’-Triacetyluridine is a prodrug of uridine .1 It is more lipid soluble than uridine and resistant to degradation by uridine phosphorylase. It is cleaved by plasma esterases in vivo to release uridine. 2’,3’,5’-Triacetyluridine (6% in the diet) decreases neurodegeneration in the piriform cortex and striatum, as well as reduces the amount of huntingtin-positive aggregates and increases BDNF protein levels in the piriform cortex in a transgenic mouse model of Huntington’s disease.2 It also improves rotarod performance and increases survival in transgenic mouse models of Huntington’s disease. 2’,3’,5’-Triacetyluridine reverses toxicity and increases survival in a mouse model of dihydropyrimidine dehydrogenase (DPD) deficiency-induced 5-fluorouracil overdose when used at a concentration of 2,000 mg/kg three times per day beginning within 24 hours of 5-FU administration.3 Formulations containing 2’,3’,5’-triacetyluridine have been used in the treatment of hereditary orotic aciduria and of overdose or life-threatening toxicity due to flurouracil or capecitabine.
1.Ashour, O.M., Naguib, F.N.M., and el Kouni, M.H.5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration: Implications for chemotherapyBiochem. Pharmacol.51(12)1601-1611(1996) 2.Saydoff, J.A., Garcia, R.A.G., Browne, S.E., et al.Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's diseaseNeurobiol. Dis.24(3)455-465(2006) 3.von Borstel, R.W., O'Neil, J.D., Saydoff, J.A., et al.Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiencyJ. Clin. Oncol.28(15_supp)e13505-e13505(2010)
| Cas No. | 4105-38-8 | SDF | |
| 别名 | 2',3',5'-三乙酰尿苷,Tri-O-acetyl uridine | ||
| Canonical SMILES | O=C(NC(C=C1)=O)N1[C@H](O2)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2COC(C)=O | ||
| 分子式 | C15H18N2O9 | 分子量 | 370.31 |
| 溶解度 | DMSO: ≥ 100 mg/mL (270.04 mM); Water: 10 mg/mL (27.00 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7004 mL | 13.5022 mL | 27.0044 mL |
| 5 mM | 0.5401 mL | 2.7004 mL | 5.4009 mL |
| 10 mM | 0.27 mL | 1.3502 mL | 2.7004 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet